Genesis versus Isomorphic Data Control

The real split is not model quality alone, it is who controls the pharma workflow and the underlying data loop. Genesis wins when a partner wants an embedded team that plugs directly into its assays, target priorities, and proprietary results, as seen in the Incyte expansion from an initial 2025 collaboration into a broader 2026 relationship. Isomorphic is selling into many of the same hard programs, but with far more capital, compute, and large pharma credibility behind it.

• Genesis is closer to a forward deployed drug design team than a software vendor. Its scientists and engineers configure GEMS around partner targets, inspect binding poses, rank tradeoffs like potency versus solubility, and feed lab results back into the next design cycle. That makes partner data integration part of the product, not an add on.
  1 sacra 2 gcsweb
• Isomorphic is pursuing the same collaboration buyers with a heavier balance sheet and broader modality pitch. It works with Novartis, Lilly, and J&J, covers small molecules, antibodies, peptides, and molecular glues, and had about $2.7B in disclosed external funding by May 2026 versus Genesis at about $296.1M.
  3 sacra 4 isomorphiclabs 5 isomorphiclabs
• Both companies are chasing difficult targets because that is where AI earns its keep. Genesis emphasizes protein ligand modeling and partner specific data compounding on hard discovery problems. Isomorphic similarly focuses on allosteric and cryptic pockets, oncology and immunology, and targets that standard screening workflows have struggled to drug.
  1 sacra 3 sacra 4 isomorphiclabs

Going forward, the edge in this segment will come from turning collaborations into compounding proprietary data and then into owned drug assets. Genesis is positioned to win teams that want a flexible co development partner inside their workflow. Isomorphic is positioned to win teams that want the biggest AI platform and the deepest capital base in the field.